Ionis reports third quarter 2025 financial results and highlights progress on key programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 42c, Beats on Revenue; Offers FY25 EPS Guidance
October 29, 2025 7:08 AM EDTIonis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.80), $0.42 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $157 million versus the consensus estimate of $130.76 million.
GUIDANCE:
Ionis Pharmaceuticals sees FY2025 EPS of $875.00-$900.00, versus the consensus of... More
